Login to Your Account

Contrave Beats the Odds

FDA Panel Backs Orexigen's Contrave in Weight Loss

By Donna Young

Wednesday, December 8, 2010
SILVER SPRING, Md. – Beating the odds, Orexigen Therapeutics Inc. won the backing of an FDA panel Tuesday for approval of the company's weight-loss drug Contrave (naltrexone/bupropion) – the only drug out of three recently reviewed at the agency to gain the Endocrinologic and Metabolic Drugs Advisory Committee's blessing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription